Literature DB >> 25149206

Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome/Bickerstaff brain stem encephalitis overlap syndrome.

Henning R Stetefeld1, Helmar C Lehmann2, Gereon R Fink3, Lothar Burghaus2.   

Abstract

The association of a posterior reversible encephalopathy syndrome (PRES) without arterial hypertension with autoimmune-mediated inflammatory neuropathies such as Guillain-Barré syndrome (GBS) is a rare and poorly understood phenomenon. To date, PRES has been described as initial manifestation, coincidental finding, or adverse event subsequent to immunomodulatory treatment with intravenous immunoglobulin (IVIG) in cases of axonal and demyelinating GBS as well as in Miller-Fisher syndrome (MFS). We here report a case of MFS/Bickerstaff brain stem encephalitis (BBE)-overlap syndrome and nonhypertensive PRES that occurred in close temporal association with IVIG treatment and caused stroke. Immunoadsorption ameliorated the disease course. Our case supports the notion that in severe cases, immunoadsorption should be considered as first-line therapy instead of IVIG for rapid removal of IgG and thus to hasten recovery and improve functional outcome.
Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bickerstaff brain stem encephalitis; Guillain-Barre syndrome; IVIG; Miller-Fisher syndrome; PRES; stroke

Mesh:

Substances:

Year:  2014        PMID: 25149206     DOI: 10.1016/j.jstrokecerebrovasdis.2014.05.034

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  7 in total

1.  Minimally symptomatic posterior reversible encephalopathy in Guillain-Barré syndrome.

Authors:  Giovanni Piccolo; Giuseppina Borutti; Diego Franciotta; Carla Arbasino; Carlo Dallocchio; Claudia Camana; Giada Gola; Maria Grazia Egitto
Journal:  Funct Neurol       Date:  2015 Jan-Mar

Review 2.  Autonomic involvement in Guillain-Barré syndrome: an update.

Authors:  Zoya Zaeem; Zaeem A Siddiqi; Douglas W Zochodne
Journal:  Clin Auton Res       Date:  2018-07-17       Impact factor: 4.435

3.  Posterior reversible encephalopathy syndrome following immunoglobulin therapy in a patient with Miller-Fisher syndrome.

Authors:  Bruno Niemeyer de Freitas Ribeiro; Tiago Medina Salata; Rafael Silveira Borges; Edson Marchiori
Journal:  Radiol Bras       Date:  2016 Jan-Feb

4.  Posterior reversible encephalopathy as the first manifestation of Bickerstaff's brainstem encephalitis.

Authors:  Pei-Ru Chen; Shih-Pin Chen
Journal:  BMC Neurol       Date:  2016-11-08       Impact factor: 2.474

5.  Vision Loss in Guillain-Barre Syndrome; a Complication or a Coincidence.

Authors:  Mahmood Dhahir Al-Mendalawi
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

Review 6.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561

7.  Late-Onset Guillain-Barré Syndrome and Right Facial Nerve Palsy after COVID-19 Infection.

Authors:  Meari Taguchi; Kyle Bonner; Anza Bilal Memon
Journal:  Case Rep Neurol       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.